Preclinical study demonstrates that HSPA8 disrupts SNARE assembly and reduces protective extracellular vesicle tau release in Alzheimer models, highlighting HSPA8 as a therapeutic target.
Background Dysregulation of multivesicular bodies (MVBs) in Alzheimer’s disease (AD) contributes to aberrant tau secretion via extracellular vesicles (EVs). This may potentially explain our previous paradoxical observation of elevated free-form p-tau217 alongside reduced p-tau217 + EVs in plasma. This study aimed to investigate the mechanisms underlying the reduction of p-tau217 + EVs to uncover AD therapeutic targets. Methods By integrating hippocampal spatial transcriptomics of human brain with EV proteomics of cerebrospinal fluid, we identified key regulators of p-tau217 + EV release. Subsequently, we investigated the mechanisms underlying the synthesis and secretion of p-tau217 + EVs. The regulatory roles of these candidate proteins were systematically evaluated through shRNA knockdown and interference with a synthetic peptide in both Aβ 42 -treated cells and AD model mice. Results Heat shock protein family A member 8 (HSPA8) was identified as a crucial regulator of EV biogenesis and release, mediating the Aβ–SNAP29 interaction to disrupt SNARE complex assembly and impair p-tau217 + EV secretion. In AD models, HSPA8 inhibition with shRNA rescued p-tau217 + EVs and improved cognitive function. Additionally, blocking the Aβ–SNAP29 interaction with a selective peptide inhibitor for HSPA8 reversed the decline in p-tau217 + EV and cognitive deficits. Conclusions These findings reveal a role of HSPA8 in regulating the MVB-mediated EV release and tau propagation, and highlight HSPA8 as a promising therapeutic target for modifying AD progression.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: